AC Immune Parkinson’s Vaccine Study Meets Safety, Immunogenicity Goals

AC Immune Parkinson’s Vaccine Study Meets Safety, Immunogenicity Goals

AC Immune (NASDAQ:ACIU) reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active immunotherapy designed to target aggregated alpha-synuclein in early Parkinson’s disease. The placebo-controlled study enrolled 34 participants, with 25 receiving ACI-7104.056 and ni

Trial of experimental Parkinson's vaccine shows positive first results

ACI-7104, AC Immune’s experimental vaccine for early Parkinson’s disease, was generally safe and triggered an immune response against aggregated alpha-synuclein, according to results from the first part of a Phase 2 trial. The findings from the VacSYn study (NCT06015841) included 34 participants, 25 who received ACI-7104 and nine who received a placebo. The company said […] The post Trial of experimental Parkinson’s vaccine shows positive initia…